1. Patients with positive malaria tests not given artemisinin-based combination therapies: a research synthesis describing under-prescription of antimalarial medicines in Africa
- Author
-
Helen E. D. Burchett, Virginia Wiseman, Siân E. Clarke, Katia Bruxvoort, Christopher J. M. Whitty, Heidi Hopkins, Evelyn K. Ansah, Obinna Onwujekwe, Shennae O'Boyle, Wilfred Fon Mbacham, Clare I R Chandler, Anthony K. Mbonye, Catherine Goodman, and Sarah G. Staedke
- Subjects
Male ,lcsh:Medicine ,Antimalarial ,Rapid diagnostic test ,Ghana ,Tanzania ,Prescription ,Case management ,0302 clinical medicine ,Health care ,Diagnosis ,Uganda ,030212 general & internal medicine ,Artemisinin ,Practice Patterns, Physicians' ,Child ,biology ,Diagnostic test ,General Medicine ,Middle Aged ,Artemisinins ,Prescriptions ,Child, Preschool ,Female ,Private Sector ,medicine.drug ,Research Article ,Adult ,medicine.medical_specialty ,Adolescent ,030231 tropical medicine ,Nigeria ,03 medical and health sciences ,Antimalarials ,Young Adult ,Internal medicine ,parasitic diseases ,medicine ,Humans ,Medical prescription ,Fever case management ,business.industry ,Public health ,lcsh:R ,Antibiotic ,biology.organism_classification ,medicine.disease ,ACT ,Malaria ,Prescribing ,business ,Delivery of Health Care - Abstract
Background There has been a successful push towards parasitological diagnosis of malaria in Africa, mainly with rapid diagnostic tests (mRDTs), which has reduced over-prescribing of artemisinin-based combination therapies (ACT) to malaria test-negative patients. The effect on prescribing for test-positive patients has received much less attention. Malaria infection in endemic Africa is often most dangerous for young children and those in low-transmission settings. This study examined non-prescription of antimalarials for patients with malaria infection demonstrated by positive mRDT results, and in particular these groups who are most vulnerable to poor outcomes if antimalarials are not given. Methods Analysis of data from 562,762 patients in 8 studies co-designed as part of the ACT Consortium, conducted 2007–2013 in children and adults, in Cameroon, Ghana, Nigeria, Tanzania, and Uganda, in a variety of public and private health care sector settings, and across a range of malaria endemic zones. Results Of 106,039 patients with positive mRDT results (median age 6 years), 7426 (7.0%) were not prescribed an ACT antimalarial. The proportion of mRDT-positive patients not prescribed ACT ranged across sites from 1.3 to 37.1%. For patients under age 5 years, 3473/44,539 (7.8%) were not prescribed an ACT, compared with 3833/60,043 (6.4%) of those aged ≥ 5 years. The proportion of Conclusions In eight studies of mRDT implementation in five African countries, substantial proportions of patients testing mRDT-positive were not prescribed an ACT antimalarial, and many were not prescribed an antimalarial at all. Patients most vulnerable to serious outcomes, children Trial registration Reported in individual primary studies.
- Published
- 2020